Terms: = Lymphoma AND CgA
58 results:
1. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review.
Neuendorff NR; Khan A; Ullrich F; Yates S; Devarakonda S; Lin RJ; von Tresckow B; Cordoba R; Artz A; Rosko AE
J Geriatr Oncol; 2024 Apr; 15(3):101734. PubMed ID: 38430810
[TBL] [Abstract] [Full Text] [Related]
2. Frailty assessment to individualize treatment in older patients with lymphoma.
Hormigo-Sanchez AI; Lopez-Garcia A; Mahillo-Fernandez I; Askari E; Morillo D; Perez-Saez MA; Riesco M; Urrutia C; Martinez-Peromingo FJ; Cordoba R; Gonzalez-Montalvo JI
Eur Geriatr Med; 2023 Dec; 14(6):1393-1402. PubMed ID: 37823983
[TBL] [Abstract] [Full Text] [Related]
3. Hand grip strength, short physical performance battery, and gait speed: key tools for function in Non-Hodgkin lymphoma.
García-Baztán A; Viguria-Alegria MC; Ramón-Espinoza MF; Tamayo-Rodríguez I; Gonzales-Montejo NJ; Martínez-Velilla N; Oteiza-Olaso J
Ann Hematol; 2023 Oct; 102(10):2823-2834. PubMed ID: 37566279
[TBL] [Abstract] [Full Text] [Related]
4. Treatment Individualization in Diffuse Large B-Cell lymphoma: Is Frailty Enough for Old Adults? An Original Article.
García-Baztán A; Oteiza-Olaso J; Gonzales-Montejo NJ; Ramón-Espinoza MF; Tamayo-Rodríguez I; Martínez-Velilla N; Viguria-Alegria MC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e348-e359. PubMed ID: 37487908
[TBL] [Abstract] [Full Text] [Related]
5. Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial.
Soo WK; King MT; Pope A; Parente P; Dārziņš P; Davis ID
Lancet Healthy Longev; 2022 Sep; 3(9):e617-e627. PubMed ID: 36102776
[TBL] [Abstract] [Full Text] [Related]
6. Chlorogenic acid suppresses miR-460a in the regulation of Bcl-2, causing interleukin-1β reduction in thiram exposed chondrocytes via caspase-3/caspase-7 pathway.
Kulyar MF; Mo Q; Yao W; Ding Y; Yan Z; Du H; Pan H; Li K; Gao J; Shahzad M; Mansoor MK; Iqbal M; Waqas M; Akhtar M; Bhutta ZA; Li J
Phytomedicine; 2022 Sep; 104():154296. PubMed ID: 35809377
[TBL] [Abstract] [Full Text] [Related]
7. Pretreatment frailty is an independent prognostic factor among elderly patients with B-cell lymphoma undergoing immunochemotherapy: A prospective observational cohort study in Taiwan.
Hung YS; Chang H; Wang PN; Kuo MC; Su YJ; Hung CY; Hsueh SW; Yeh KY; Ho YW; Chou WC
Asia Pac J Clin Oncol; 2023 Feb; 19(1):62-70. PubMed ID: 35403372
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma.
Tanaka T; Sakai R; Choi I; Tsukada J; Sasaki H; Naito Y; Kiyomi F; Takamatsu Y; Tamura K
Sci Rep; 2022 Feb; 12(1):3124. PubMed ID: 35210509
[TBL] [Abstract] [Full Text] [Related]
9. [Clinicopathological characteristics of SMARCB1(INI1)-deficient sinonasal carcinoma].
Wang JY; Bai YP; Xing L; Piao YS; He XJ; Yue CL; Zhao XL; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1240-1245. PubMed ID: 34719161
[No Abstract] [Full Text] [Related]
10. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.
Brem EA; Li H; Beaven AW; Caimi PF; Cerchietti L; Alizadeh AA; Olin R; Henry NL; Dillon H; Little RF; Laubach C; LeBlanc M; Friedberg JW; Smith SM
J Geriatr Oncol; 2022 Mar; 13(2):258-264. PubMed ID: 34686472
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.
Zhang H; Liu M; Li Q; Lyu C; Jiang YY; Meng JX; Li JY; Deng Q
Leuk Lymphoma; 2022 Feb; 63(2):353-361. PubMed ID: 34587859
[TBL] [Abstract] [Full Text] [Related]
12. Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study.
Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
Eur Geriatr Med; 2022 Feb; 13(1):195-201. PubMed ID: 34254266
[TBL] [Abstract] [Full Text] [Related]
13. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.
Srour SA; Saliba RM; Bashir Q; Popat UR; Ahmed S; Mehta RS; Delgado R; Rondon G; Parmar S; Kebriaei P; Hosing C; Manasanch EE; Lee HC; Patel KK; Orlowski RZ; Shpall E; Champlin RE; Qazilbash MH; Nieto Y
Transplant Cell Ther; 2021 Mar; 27(3):243.e1-243.e6. PubMed ID: 33781521
[TBL] [Abstract] [Full Text] [Related]
14. Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies.
Garric M; Sourdet S; Cabarrou B; Steinmeyer Z; Gauthier M; Ysebaert L; Beyne-Rauzy O; Gerard S; Lozano S; Brechemier D; Filleron T; Mourey L; Balardy L
Eur J Haematol; 2021 May; 106(5):616-626. PubMed ID: 33340150
[TBL] [Abstract] [Full Text] [Related]
15. Quality of life in older survivors of non-Hodgkin's lymphoma who received chemotherapy and related factors.
Ariestine DA; Sari NK; Rinaldi I; Abdullah M
J Geriatr Oncol; 2021 Mar; 12(2):326-331. PubMed ID: 33008767
[TBL] [Abstract] [Full Text] [Related]
16. Diffuse Large B-Cell lymphoma in the Elderly: Current Approaches.
Allen P
Curr Oncol Rep; 2020 Aug; 22(11):114. PubMed ID: 32827063
[TBL] [Abstract] [Full Text] [Related]
17. Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy.
Chou WC; Chang H; Wang PN; Kuo MC; Wu JH; Lin TL; Su YJ; Kao HW; Ou CW; Hung CY; Hsueh SW; Hung YS
Eur J Haematol; 2020 Oct; 105(4):399-407. PubMed ID: 32472712
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive Geriatric Assessment (cga): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
Ong DM; Ashby M; Grigg A; Gard G; Ng ZY; Huang HE; Chong YS; Cheah CY; Devitt B; Chong G; Loh Z; Mo A; Hawkes EA
Br J Haematol; 2019 Oct; 187(1):73-81. PubMed ID: 31206608
[TBL] [Abstract] [Full Text] [Related]
20. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract] [Full Text] [Related]
[Next]
